Eric K. Rowinsky
Eric K. Rowinsky's purchase track record
Eric K. Rowinsky has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/15/2024 | BIIB | $101K | +3.0% | -9.7% | +10.2% |
| 2/10/2023 | FBIO | $10K | -5.3% | -30.3% | +9.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Verastem presents ovarian cancer data at IGCS, outlines pipeline. Verastem Oncology reported a late‑breaking oral presentation of its RAMP 201 low‑grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The company also highlighted the launch of its ovarian cancer therapy and progress on the KRAS G12D program during an H.C. Wainwright event. These updates reflect ongoing clinical development and investor communication around its oncology pipeline.
Transaction History
| BIIB | ▲ Buy | Grant | 1,505 | $0 | 6/9/2026 | View on chart |
| VSTM | ▲ Buy | Grant | 36,000 | $0 | 5/21/2026 | View on chart |
| BIIB | ▲ Buy | Grant | 2,370 | $0 | 6/17/2025 | View on chart |
| VSTM | ▲ Buy | Grant | 8,333 | $0 | 5/22/2025 | View on chart |
| BIIB | ▲ Buy | Grant | 1,340 | $0 | 6/21/2024 | View on chart |
| VSTM | ▲ Buy | Grant | 8,333 | $0 | 6/18/2024 | View on chart |
| BIIB | ▲ Buy | Open Market | 455 | $101K | 2/15/2024 | View on chart |
| FBIO | ▲ Buy | Grant | 6,666 | $0 | 1/1/2024 | View on chart |
| BIIB | ▲ Buy | Grant | 960 | $0 | 6/26/2023 | View on chart |
| FBIO | ▲ Buy | Open Market | 11,976 | $10K | 2/10/2023 | View on chart |
| FBIO | ▲ Buy | Grant | 100,000 | $0 | 1/1/2023 | View on chart |
| BIIB | ▲ Buy | Grant | 1,370 | $0 | 6/15/2022 | View on chart |
| FBIO | ▲ Buy | Grant | 100,000 | $0 | 1/1/2022 | View on chart |
| VSTM | ▲ Buy | Open Market | 2,000 | $8K | 9/5/2017 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade
Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.